Market closed
Verve Therapeutics/$VERV
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Verve Therapeutics
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Ticker
$VERV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
255
Website
VERV Metrics
BasicAdvanced
$616M
-
-$2.45
1.76
-
Price and volume
Market cap
$616M
Beta
1.76
52-week high
$19.34
52-week low
$4.31
Average daily volume
1.6M
Financial strength
Current ratio
13.05
Quick ratio
12.723
Long term debt to equity
11.973
Total debt to equity
14.011
Management effectiveness
Return on assets (TTM)
-22.19%
Return on equity (TTM)
-40.67%
Valuation
Price to revenue (TTM)
24.002
Price to book
1.21
Price to tangible book (TTM)
1.21
Price to free cash flow (TTM)
-3.613
Growth
Revenue change (TTM)
219.91%
Earnings per share change (TTM)
-21.06%
3-year earnings per share growth (CAGR)
-30.53%
What the Analysts think about VERV
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Verve Therapeutics stock.
VERV Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VERV Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VERV News
AllArticlesVideos
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
GlobeNewsWire·4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Verve Therapeutics stock?
Verve Therapeutics (VERV) has a market cap of $616M as of February 25, 2025.
What is the P/E ratio for Verve Therapeutics stock?
The price to earnings (P/E) ratio for Verve Therapeutics (VERV) stock is 0 as of February 25, 2025.
Does Verve Therapeutics stock pay dividends?
No, Verve Therapeutics (VERV) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Verve Therapeutics dividend payment date?
Verve Therapeutics (VERV) stock does not pay dividends to its shareholders.
What is the beta indicator for Verve Therapeutics?
Verve Therapeutics (VERV) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.